Take-Home Points for the Treatment of AMD and DME
David A. Eichenbaum, MD, FASRS and Caroline Baumal, MD provide take-home messages to providers treating AMD and DME.
Unmet Needs in AMD and DME
Drs David A. Eichenbaum and Caroline Baumal discuss unmet needs in treating AMD and DME.
Incorporating Faricimab in Clinical Practice
Retina specialists discuss how to incorporate faricimab into clinical practice and discuss implacations of the TRUCKEE study.
MOA of Faricimab and 2-Year Data Review
David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, review the dual mechanism of action of faricimab as well as the 2-year update in the TENAYA, LUCERNE, YOSEMITE, and RHINE trials.
Implications of Treat-and-Extend With Faricimab in AMD
Drs David A. Eichenbaum and Caroline Baumal discuss implications of the treat-and-extend approach with faricimab in patients with wet AMD.
AMD and DME: Factors Affecting Treatment Selection and the Importance of Shared Decision-Making
Retina specialists discuss which factors impact treatment selection and how to incorporate shared decision-making into treatment selection when treating patients with AMD and DME.
Impact of AMD and DME on Quality of Life
David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, discuss how AMD and DME impact a patient’s quality of life.
Parafoveal retinal vessel density assessment by OCTA in healthy eyes
Study aims to identify methodology for least amount of variation, greatest test-retest reliability
2 Clarke Drive Cranbury, NJ 08512